157 results
Page 5 of 8
8-K
EX-99.1
clyjgbjchopy4
31 Oct 19
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
7:39am
8-K
EX-99.1
cx7x6qdua5
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
qrvn2qyhrrhma1odgg
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
y6w6x3yj5jz2q 3os2d
4 Sep 19
Other Events
5:05pm
8-K
EX-99.1
ruxtzfs
1 Aug 19
Agios Reports Business Highlights and Second Quarter 2019 Financial Results
7:29am
8-K
EX-99.1
i0kmk5
3 Jun 19
Other Events
4:02pm
8-K
EX-99.1
67tfrkl 86z94w61j0bp
15 May 19
Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma
4:13pm
8-K
EX-99.1
rmme5yx mk
2 May 19
Other Events
3:24pm
8-K
EX-99.1
bf8k264q
2 May 19
Agios Reports Business Highlights and First Quarter 2019 Financial Results
7:24am
8-K
EX-99.1
3iq27gs1q83xzuzhp1
14 Feb 19
Agios Reports Fourth Quarter and Full Year 2018 Financial Results
7:16am
8-K
EX-99.1
tjbzqyqt8m9 hvfrdu
7 Jan 19
Agios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value
7:48am
8-K
EX-99.1
3qt1m6z 6a
3 Dec 18
Other Events
4:03pm
8-K
EX-99.2
x8feaj
3 Dec 18
Other Events
4:03pm
8-K
EX-99.1
egv5xnoh0 rza8aqn
16 Nov 18
Agios Presents Updated Data from Phase 1 Dose-Escalation Study ofAG-881 in Patients with IDH Mutant Positive Advanced Glioma
4:01pm
8-K
EX-99.1
qpqzv9 4hboo6th019v
1 Nov 18
Agios Reports Third Quarter 2018 Financial Results
7:45am